Table 1 Baseline characteristics before propensity score matching
Variable | R group | L group | P value |
|---|---|---|---|
n = 523 | n = 177 | ||
Sex (male) | 452 (86.4%) | 146 (82.5%) | 0.246 |
Poor differentiation | 204 (39.0%) | 76 (42.9%) | 0.291 |
Lymphatic metastasis | 2 (0.4%) | 2 (1.1%) | 0.573 |
Cirrhosis | 327 (62.5%) | 121 (68.4%) | 0.191 |
MVI | 156 (29.8%) | 75 (42.4%) | 0.003 |
Satellite nodules | 77 (14.7%) | 24 (13.6%) | 0.797 |
Tumor number (single) | 470 (89.9%) | 154 (87.0%) | 0.220 |
GVI | 41 (7.8%) | 18 (10.2%) | 0.419 |
Invading adjacent organs | 7 (1.3%) | 0 (0.0%) | 0.267 |
Positive HBsAg | 463 (88.5%) | 151 (85.3%) | 0.320 |
Positive HBeAg | 96 (18.4%) | 38 (21.5%) | 0.424 |
AFP (< 400 ng/mL) | 317 (60.6%) | 98 (55.4%) | 0.255 |
Age (year) (IQR) | 49.0 (42.0–58.0) | 49.0 (41.0–58.0) | 0.692 |
Tumor diameter (cm) (IQR) | 5.0 (3.6–8.0) | 5.0 (3.5–8.0) | 0.772 |
NEU count (109/L) (IQR) | 3.25 (2.46–4.23) | 2.99 (2.39–4.09) | 0.125 |
LYM count (109/L) (IQR) | 1.45 (1.16–1.80) | 1.44 (1.05–1.83) | 0.339 |
PLA count (109/L) (IQR) | 129.0 (89.0–184.0) | 128.0 (88.5–170.0) | 0.373 |
TBIL level (mmol/L) (IQR) | 14.30 (10.70–18.30) | 13.40 (10.15–17.75) | 0.085 |
ALT level (U/L) (IQR) | 42.00 (28.00–66.00) | 39.00 (26.00–57.00) | 0.042 |
AST level (U/L) (IQR) | 39.00 (29.00–56.00) | 38.00 (29.00–52.00) | 0.389 |
ALB g/dL (IQR) | 41.80 (39.10–44.90) | 41.60 (39.10–43.95) | 0.342 |
BCLC | |||
0 | 235 (44.9%) | 86 (48.6%) | 0.124 |
A | 209 (40.0%) | 55 (31.1%) | |
B | 37 (7.1%) | 19 (10.7%) | |
C | 42 (8.0%) | 17 (9.6%) | |